<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01422746</url>
  </required_header>
  <id_info>
    <org_study_id>19302</org_study_id>
    <secondary_id>CBS006</secondary_id>
    <nct_id>NCT01422746</nct_id>
  </id_info>
  <brief_title>Effect of Metformin on Adrenal or Ovarian Androgen Production in Overweight Pubertal Girls With Androgen Excess</brief_title>
  <official_title>Effect of Metformin on Adrenal or Ovarian Androgen Production in Overweight Pubertal Girls With Androgen Excess (CBS005)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Virginia</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Virginia</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will test whether metformin administration can ameliorate androgen (male hormone)&#xD;
      overproduction in overweight pubertal girls with androgen excess. The investigators&#xD;
      hypothesize that improvement in insulin sensitivity by 12 weeks of metformin administration&#xD;
      will improve androgen levels after adrenal stimulation testing with adrenocorticotropic&#xD;
      hormone (ACTH) or ovarian stimulation testing with recombinant human chorionic gonadotropin&#xD;
      (rhCG).&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 20, 2017</start_date>
  <completion_date type="Anticipated">December 2021</completion_date>
  <primary_completion_date type="Anticipated">December 2021</primary_completion_date>
  <phase>Early Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Changes in free testosterone or 17-hydroxyprogesterone levels after ACTH and rhCG administration respectively, before and after metformin administration for 12 weeks</measure>
    <time_frame>12 weeks after metformin administration</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Changes in adrenal and ovarian steroid precursors after ACTH and rhCG; body composition via air displacement plethysmography, BMI, and glucose tolerance testing results; baseline and after 12 weeks of metformin administration</measure>
    <time_frame>12 weeks after metformin administration</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Obesity</condition>
  <condition>Hyperandrogenemia</condition>
  <condition>Polycystic Ovary Syndrome</condition>
  <arm_group>
    <arm_group_label>metformin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>12 weeks metformin, with pre- and post- dexamethasone and ACTH to perform standardized adrenal stimulation testing; dexamethasone and rhCG to perform standardized ovarian stimulation testing</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Metformin</intervention_name>
    <description>500-1000 mg PO BID (X12 weeks)</description>
    <arm_group_label>metformin</arm_group_label>
    <other_name>Glucophage</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Overweight(&gt;85th BMI%) females&#xD;
&#xD;
          -  Early to late puberty (expected age range 7-18)&#xD;
&#xD;
          -  Hyperandrogenemic (free testosterone greater than 2.5 standard deviations above the&#xD;
             mean for normal control subjects of the same Tanner Stage)&#xD;
&#xD;
          -  Screening labs within age-appropriate normal range, with the exception of a mildly low&#xD;
             hematocrit (see below) and the hormonal abnormalities inherent in obesity which could&#xD;
             include mildly elevated luteinizing hormone (LH), lipids, testosterone, prolactin,&#xD;
             DHEAS, E2, glucose, and insulin; and decreased follicle-stimulating hormone (FSH)&#xD;
             and/or sex hormone-binding globulin (SHBG)&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Age &lt; 7 or &gt; 18 y&#xD;
&#xD;
          -  Inability to comprehend what will be done during the study or why it will be done&#xD;
&#xD;
          -  BMI-for-age &lt; 5th percentile&#xD;
&#xD;
          -  Positive pregnancy test or lactation.&#xD;
&#xD;
          -  Abnormal laboratory studies will be confirmed by repeat testing to exclude laboratory&#xD;
             error.&#xD;
&#xD;
          -  Morning cortisol &lt; 3 µg/dL or history of Cushing syndrome or adrenal insufficiency&#xD;
&#xD;
          -  History of congenital adrenal hyperplasia or 17-hydroxyprogesterone &gt; 300 ng/dL, which&#xD;
             suggests the possibility of congenital adrenal hyperplasia (if postmenarcheal, the&#xD;
             17-hydroxyprogesterone will be collected during the follicular phase, or ≥ 40 days&#xD;
             since last menses if oligomenorrheic). NOTE: If a 17-hydroxyprogesterone &gt;300 mg/dL is&#xD;
             confirmed on repeat testing, an ACTH-stimulated 17-hydroxyprogesterone &lt;1000 ng/dL&#xD;
             will be required for study participation.&#xD;
&#xD;
          -  Total testosterone &gt; 150 ng/dL, which suggests the possibility of a virilizing&#xD;
             neoplasm&#xD;
&#xD;
          -  DHEAS greater than the upper limit of age-appropriate normal range (mild elevations&#xD;
             may be seen in polycystic ovary syndrome (PCOS) and adolescent hyperandrogenemia (HA),&#xD;
             and elevations &lt; 1.5 times the age-appropriate upper limit of normal will be accepted&#xD;
             in these groups)&#xD;
&#xD;
          -  Virilization&#xD;
&#xD;
          -  Previous diagnosis of diabetes, fasting glucose ≥126 mg/dL, or a hemoglobin A1c ≥6.5%&#xD;
&#xD;
          -  Abnormal thyroid stimulating hormone (TSH) for age. Subjects with stable and&#xD;
             adequately treated hypothyroidism, reflected by normal TSH values, will not be&#xD;
             excluded.&#xD;
&#xD;
          -  Abnormal prolactin. Mild elevations may be seen in overweight girls, and elevations&#xD;
             &lt;1.5 times the upper limit of normal will be accepted in this group.&#xD;
&#xD;
          -  Persistent hematocrit &lt;36% and hemoglobin &lt;12 g/dL. Subjects with a mildly low&#xD;
             hematocrit (33-36%) will be asked to take iron in the form of ferrous gluconate for up&#xD;
             to 60 days. Subjects weighing ≤ 36 kg will take one 300-325 mg tablet oral ferrous&#xD;
             gluconate daily (containing 36 mg elemental iron);subjects weighing &gt;36 kg will take&#xD;
             two 300-325 mg tablets oral ferrous gluconate daily (containing 36 mg elemental iron&#xD;
             each). They will return to the Clinical Research Unit (CRU) after 30-60 days of iron&#xD;
             therapy to have their hemoglobin or hematocrit rechecked and will proceed with the&#xD;
             remainder of the study if it is ≥12 g/dL or ≥36%, respectively.&#xD;
&#xD;
          -  Persistent liver test abnormalities, with the exception that mild bilirubin elevations&#xD;
             will be accepted in the setting of known Gilbert's syndrome. Mild elevations may be&#xD;
             seen in overweight girls, so elevations &lt;1.5 times the upper limit of normal will be&#xD;
             accepted in this group.&#xD;
&#xD;
          -  Significant history of cardiac or pulmonary dysfunction (e.g., known or suspected&#xD;
             congestive heart failure; asthma requiring intermittent systemic corticosteroids;&#xD;
             etc.)&#xD;
&#xD;
          -  Abnormal sodium, potassium, or bicarbonate concentrations, or elevated creatinine&#xD;
             concentration (confirmed on repeat)&#xD;
&#xD;
          -  No medications known to affect the reproductive system or glucose metabolism can be&#xD;
             taken in the 3 months prior to the study. Such medications include oral contraceptive&#xD;
             pills, progestins, metformin, glucocorticoids, and psychotropics.&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>7 Years</minimum_age>
    <maximum_age>18 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Christine Burt Solorzano, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Virginia</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Melissa Gilrain</last_name>
    <phone>434-243-6911</phone>
    <email>pcos@virginia.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Christine Burt Solorzano, MD</last_name>
    <phone>434-243-6911</phone>
    <email>pcos@virginia.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University of Virginia Center for Research in Reproduction</name>
      <address>
        <city>Charlottesville</city>
        <state>Virginia</state>
        <zip>22908</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Melissa Gilrain</last_name>
      <phone>434-243-6911</phone>
      <email>pcos@virginia.edu</email>
    </contact>
    <investigator>
      <last_name>Christine Burt Solorzano, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>John C. Marshall, MD, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2020</verification_date>
  <study_first_submitted>August 22, 2011</study_first_submitted>
  <study_first_submitted_qc>August 23, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 24, 2011</study_first_posted>
  <last_update_submitted>November 18, 2020</last_update_submitted>
  <last_update_submitted_qc>November 18, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">November 20, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Virginia</investigator_affiliation>
    <investigator_full_name>Christine Burt Solorzano</investigator_full_name>
    <investigator_title>Assistant Professor of Pediatrics</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Polycystic Ovary Syndrome</mesh_term>
    <mesh_term>Hyperandrogenism</mesh_term>
    <mesh_term>Overweight</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Metformin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

